Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A · kind A · utility
86Cited by
12References
106Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 1999 |
| Grant date | Oct 3, 2000 |
| Priority date | — |
| Expiry date | Nov 10, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is local, i.e., transurethral, intracavernosal, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.